Hem/Onc Roundup: Dr. Cortes Discusses Ponatinib for CML; Plus, Liquid Biopsy for Pancreatic Cancer

This week on DocWire News, editors spoke with Dr. Jorge Cortes, Director of the Georgia Cancer Center, about the approval of ponatinib for adults with chronic-phase chronic myeloid leukemia (CML), and why it’s important to continue research into this agent for chronic-phase CML.

Dr. Cortes Discusses Approval of Ponatinib for Adults with Chronic-phase CML

Residing in areas with high levels of artificial light at night exposure may increases your risk of developing thyroid cancer, according to a new study published in the journal CANCER. In an analysis of more than 464,000 participants, researchers found that individuals living in areas with the highest artificial light exposure at nighttime had a 55% higher risk of thyroid cancer. This association was stronger in women than in men.

Exposure of Artificial Nighttime Light Linked to Thyroid Cancer

Researchers from the Mayo Clinic examined the feasibility of utilizing circulating tumor DNA (ctDNA) profiling to diagnosis pancreatic ductal adenocarcinoma (PDAC). “PDAC has a poor prognosis often due to late presentation of disease. Biopsy tissue sampling is invasive, and samples are often inadequate, requiring repeated invasive procedures and delays in treatment,” wrote the study authors. “Non‐invasive methods to identify PDAC early in its course may improve prognosis.”

Utilizing Liquid Biopsy to Diagnose Pancreatic Cancer

For many years, the mortality rates of breast cancer were on the decline among younger women. However, this trend appears to be reversing, according to new data from a retrospective review. After 2010, in women aged 20 to 29 years, breast cancer mortality rates increased by 2.8% per year, and by 0.3% per year in women aged 30 to 39 years.

Breast Cancer Mortality Rates Are No Longer Declining In Younger Women